bimagrumab human monoclonal antibody developed novartis treat pathological muscle loss weakness binds inhibits activin receptor bimagrumab must administered intravenously hospital clinic medication long half life administered august announced bimagrumab received breakthrough therapy designation sporadic inclusion body myositis sibm us food drug bimagrumab entered phase ii development research indicating clinical novartis planned apply fda approval treat sibm patients april novartis announced bimagrumab failed phase iibiii study sporadic inclusion body january new study confirmed treatment bimagrumab safe effective treating excess adiposity metabolic disturbances adult patients obesity type january medication entered phase iib trials immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding ithttpsenwikipediaorgwikibimagrumab